In the assessment of 12-month price targets, analysts unveil insights for Exelixis, presenting an average target of $37.74, a high estimate of $45.00, and a low estimate of $29.00. Observing a 3.91% ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Several states are reporting cases of measles, a highly contagious viral disease. Both children and adults can get measles.

19 analysts have expressed a variety of opinions on Exelixis (NASDAQ:EXEL) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table summarizes their ...

Older adults with cancer respond just as well as younger patients to immune checkpoint inhibitors despite age-related immune ...

Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Older adults with cancer respond just as well as younger patients to immune checkpoint inhibitors despite age-related immune system differences ...

Alameda, CA-based Exelixis, Inc. is an oncology-focused biotechnology company that primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult ...

The National Cancer Institute’s Investigational New Drug program facilitates collaboration, not collusion, with industry for ...